High Net Worth Advisory Group’s Keros Therapeutics KROS Stock Holding History

High Net Worth Advisory Group’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-500	Closed	-$14K	–	703
2022 Q2	$14K	Hold	500	–	–	0.01%	496
2022 Q1	$27K	Hold	500	–	–	0.01%	414
2021 Q4	$29K	Buy	+500	New	+$24.9K	0.01%	411

Other funds holding KROS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

High Net Worth Advisory Group's KROS Position: Q3 2022 in Review

High Net Worth Advisory Group sold out of Keros Therapeutics (KROS) in Q3 2022, closing a stake of 500 shares — an estimated $14K sold.

High Net Worth Advisory Group first reported a position in KROS in Q4 2021 and held it in 3 quarters. The position peaked at $29K in Q4 2021. 113 funds tracked by Wall St. Rank hold KROS as of Q3 2022.

High Net Worth Advisory Group reported no remaining Keros Therapeutics position as of Q3 2022 after selling out during the quarter.
High Net Worth Advisory Group sold 500 Keros Therapeutics shares in Q3 2022, an estimated $14K.
High Net Worth Advisory Group first reported a position in Keros Therapeutics in Q4 2021 and held it in 3 quarters.
High Net Worth Advisory Group's Keros Therapeutics position peaked at $29K in Q4 2021.
113 funds tracked by Wall St. Rank held Keros Therapeutics as of Q3 2022.

Based on High Net Worth Advisory Group's 13F filing for Q3 2022, filed 24 Oct 2022.